entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 18:20:36 - browse：945

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Industry veterans launch new biotech VC with $310M

Wikipedia

focus

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

Sea level rise could wash away turtle breeding grounds around the world, researchers say

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Biogen Alzheimer’s drug launch off to slow start

To avoid data mishandling cases, universities eye AI and other tools

Why did Pfizer dish out millions for a Super Bowl ad?

leisure time

entertainment

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

What does generative AI mean for health care? We asked experts

The dental labor crisis is a moment of opportunity

Peter Hotez and the public health issue of online harassment

Industry veterans launch new biotech VC with $310M

New air purifier tech could be key to improving indoor air quality

PhRMA lawsuit over Medicare drug price negotiation tossed

Psychedelics group wrestles with new pharma identity

A disappointing year of Humira biosimilars

explore

How to fix the rural physician shortage in the U.S.

Can medical device makers keep up in the race to treat obesity?

Xenotransplantation trials will require adjusting expectations, experts say

PhRMA lawsuit over Medicare drug price negotiation tossed

'Revelatory' study finds a smoking impact that remains after quitting

Robert F. Kennedy is pitching centrism on health, even on abortion

knowledge

Wikipedia

focus

entertainment